A fixed-dose combination lotion comprised of halobetasol propionate 0.01% and tazarotene 0.045% (HP/TAZ) is more effective for treating moderate-to-severe plaque psoriasis than either component alone.
Tildrakizumab therapy was examined in patients with moderate-to-severe plaque psoriasis.
Investigators observed that conjunctivitis is more common with dupilumab treatment in clinical trials of patients with atopic dermatitis than trials in patients with asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
Investigators examined CDH19 and DLL3 expression and corresponding BiTE® antibody constructs activity in a panel of 14 melanoma cell lines that originated from patients who were resistant to either targeted therapy or immune checkpoint therapy.
Investigators assessed the risk for herpes zoster and provided recommendations regarding treatment in patients with psoriasis.
Little evidence exists to demonstrate the efficacy of antistreptococcal treatments for guttate and chronic plaque psoriasis.
Dupilumab demonstrated similar efficacy to that seen in clinical trials, but higher rates of conjunctivitis and eosinophilia.
Researchers used a standardization method to predict the difference in the incidence of severe adverse events and the response rate between RCT and real-world populations of patients receiving biologic therapies for psoriasis.
Injectable dermal filler polymethylmethacrylate may be used to effectively treat full-face acne scarring.
The ACIP and CDC have approved and released 2019 recommendations for the adult immunization schedule in the US.
